Background As a novel immune checkpoint molecular, T-cell immunoglobulin mucin 3 (TIM-
3) is emerging as a therapeutic target for cancer immunotherapy. However, the predictive …

Background Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited
efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A …

Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by poor
prognosis and a low 5-year survival rate. Drug treatment is proving to be effective in anti …

Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and
an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA …

Background & Aims The presence of multifocal tumors, developed either from intrahepatic
metastasis (IM) or multicentric occurrence (MO), is a distinct feature of hepatocellular …

Background YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) has been indicated
proven to participate in the cross-presentation of tumor antigens in dendritic cells and the …

The present study aimed to investigate the effects of transarterial chemoembolization
(TACE) on the immune function of patients with hepatocellular carcinoma (HCC). A total of …

Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the
fourth highest number of deaths each year. HCC results from a combination of …

Systematic interrogation of tumor-infiltrating immune cells (TIICs) is key to the prediction of
clinical outcome and development of immunotherapies. However, little is known about the …

Abstract Anti-programmed cell death-1 (PD-1) antibodies has been approved to treat HCC.
Some PD-1 ligands (PD–L1 and PD–L2) negative tumors respond to treatment of anti-PD-1 …